STRYKER CORP SYK revenue by segment, product and geography
In its fiscal year ending 2025-12-31, STRYKER CORP reported revenue across 2 business segments; the largest, Med Surg And Neurotechnology, was $15.6B, 62.3% of the filed sum (+15.7% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Med Surg And Neurotechnology$15.6B62.3%+15.7% yoy
- Orthopaedics And Spine$9.47B37.7%+4.3% yoy
Members sum to the consolidated $25.1B for this period.
- United States$19Bshare n/a+12.2% yoy
- Outside the United States$6.11Bshare n/a+8.1% yoy
- EMEA$3.18Bshare n/a+9.8% yoy
- Asia Pacific$2.16Bshare n/a+7.1% yoy
- Other Foreign Countries$765Mshare n/a+4.1% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Med Surg And Neurotechnology$3.63B55.0%+9.7% yoy
- Orthopaedics And Spine$2.96B45.0%+9.1% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.